Essais cliniques près de Vancouver : mélanome
15 essais en recrutement dans le registre officiel · mis à jour en juillet 2026 · gratuit · sans compte · sans pistage · English & français
Les recherches dans un rayon de 160 km incluent volontairement les sites de l'autre côté de la frontière américaine — souvent l'option la plus proche pour un patient canadien.
Chercher près de chez vous →LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
Recruiting nowPhase 214 sites
This study is being done to answer the following question: Can the chance of melanoma growing or spreading be lowered by receiving a treatment called LND101 for Fecal Microbiota Transplant (FMT) in addition to the usual immunotherapy treatm…
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Recruiting nowPhase 382 sites
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, …
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Recruiting nowPhase 366 sites
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended…
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Recruiting nowPhase 371 sites
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Recruiting nowPhase 330 sites
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if…
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Recruiting nowPhase 2331 sites
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimet…
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
Recruiting nowPhase 37 sites
As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection. In particular, long-term use of these drugs increases the risk of skin cancer. S…
Project: Every Child for Younger Patients With Cancer
Recruiting now278 sites
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going car…
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Recruiting now467 sites
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies w…
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Opening soonPhase 258 sites
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS…
Questions fréquentes
Comment trouver un essai clinique (mélanome) près de chez moi au Canada ?
Utilisez la recherche gratuite de Beacon : entrez « mélanome », votre âge et votre lieu, et vous verrez les essais en recrutement triés par distance, chacun expliqué en langage clair — y compris les sites juste de l'autre côté de la frontière américaine. Beacon interroge le registre officiel complet et n'exige jamais de compte.
Participer à un essai clinique coûte-t-il de l'argent ?
Le traitement à l'étude et les examens liés à l'étude sont habituellement fournis sans frais, et certains essais aident avec les déplacements. Au Canada, votre régime provincial d'assurance maladie continue de couvrir vos soins courants — confirmez toujours les détails avec l'équipe de l'étude.
Puis-je quitter un essai clinique après y avoir adhéré ?
Oui. La participation est toujours volontaire et vous pouvez quitter un essai à tout moment, pour n'importe quelle raison, sans perdre vos soins médicaux habituels.
Suis-je admissible à ces essais ?
Chaque essai a ses propres critères d'admissibilité. Beacon traduit les critères de chaque essai en une liste en langage clair que vous pouvez passer en revue et apporter à votre médecin — seule l'équipe de l'étude peut confirmer votre admissibilité.
Page mise à jour en juillet 2026.